Investment led by aMoon will support US and EU commercialisation and development of advanced gastrointestinal diagnostics

Magentiq Eye, a digital health company developing AI-based software for gastrointestinal diagnostics, has completed its Series A funding round to support the global expansion of its colonoscopy decision-support technology.

The round was led by aMoon, Israel’s largest health tech-focused investment fund, and joined by Norgine Ventures (Netherlands), Nina Capital (EU and USA), Namarel Ventures (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA). Following the investment, Roy Wiesner, partner at aMoon, will join Magentiq Eye’s board of directors.

The company’s flagship product, Magentiq-Colo, is an FDA- and CE-cleared software platform that supports physicians during colonoscopies by improving the detection and classification of polyps. It provides real-time visual insights, and its CE-approved version includes polyp-type and size estimation features along with automated reporting.

“This investment round marks a major milestone for Magentiq Eye. We are thrilled to welcome aMoon and Roy Wiesner to our journey,” said Dror Zur, PhD, founder and CEO of Magentiq Eye. “With aMoon’s support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the US and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world.”

The Series A funding will support the company’s commercial rollout in the USA and Europe, as well as the development of new AI-powered tools for upper and lower GI indications, including diagnostic software for ulcerative colitis, early dysplasia in Barrett’s esophagus, and gastric intestinal metaplasia.

“We are proud to partner with Magentiq Eye, a company leading the charge in AI-powered colonoscopy,” said Wiesner. “Magentiq’s solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications. We’re also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate. This investment reflects aMoon’s commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide.”

Magentiq Eye is also developing automated quality indicators for endoscopic procedures and plans to expand its market reach through new partnerships with industry stakeholders.